狼疮肾炎肾脏缓解后免疫抑制剂停用:复发预测因素、停药时间及长期结局
该起始队列纳入137例狼疮肾炎患者,评估免疫抑制剂减量与停用的预测因素及长期结局。减量期间肾复发与较晚达完全肾脏缓解及减量开始时较高SLEDAI-2K相关;停用后复发与未持续使用羟氯喹及停用前12个月较高SLEDAI-2K相关。减量期间复发者长期不良结局更常见,膜性狼疮肾炎较增殖性更早停用免疫抑制剂。
要点
- 达完全肾脏缓解时间越长(OR 1.07)及减量开始时SLEDAI-2K越高(OR 2.57)与减量期间肾复发风险升高相关。
- 持续使用羟氯喹(≥2/3随访,OR 0.28)及停用前12个月较低SLEDAI-2K(OR 1.70)降低停用后复发风险。
- 减量期间复发者长期不良结局更常见(53% vs 16%),停用达成者与非达成者间无差异。
核心结论
- 较早达完全肾脏缓解及减量开始时较低SLEDAI-2K可预防免疫抑制剂减量期间复发。
- 持续使用羟氯喹及停用前12个月较低SLEDAI-2K可预防停用后复发;减量期间复发增加长期不良结局风险。
- 膜性狼疮肾炎较早停用免疫抑制剂是可行的。
研究设计与样本
- 研究为起始队列分析,纳入137例狼疮肾炎患者。
- 采用逻辑回归和线性回归模型分析减量及停用期间复发的决定因素、停用达成、停用时间及长期不良结局。
主要发现
- 111例(81%)尝试免疫抑制剂减量,67.5%达成停用。
- 减量期间肾复发与较晚达完全肾脏缓解相关(OR 1.07,P=0.046),与减量开始时较高SLEDAI-2K相关(OR 2.57,P=0.008)。
- 停用后复发风险降低与持续使用羟氯喹相关(OR 0.28,P=0.08),与停用前12个月较低SLEDAI-2K相关(OR 1.70,P=0.013)。
- 末次随访(中位124个月)时不良结局在减量期间复发者中更常见(53% vs 16%,P<0.0038),在停用达成者与非达成者间无差异。
- 在增殖性狼疮肾炎中,除停用时间外,差异与整个队列一致;膜性狼疮肾炎较增殖性狼疮肾炎停用时间早20个月(β=-19.8,P=0.014)。
关键数值与推荐
- 减量期间肾复发风险:达完全肾脏缓解时间每延长一单位OR 1.07(P=0.046),减量开始时SLEDAI-2K每增加一分OR 2.57(P=0.008)。
- 停用后复发风险:持续使用羟氯喹(≥2/3随访)OR 0.28(P=0.08),停用前12个月SLEDAI-2K每增加一分OR 1.70(P=0.013)。
- 长期不良结局:减量期间复发者53% vs 无复发者16%(P<0.0038)。
临床怎么用
- 对于狼疮肾炎患者,较早达完全肾脏缓解及减量开始时较低SLEDAI-2K可能有助于预防免疫抑制剂减量期间复发。
- 持续使用羟氯喹及停用前12个月较低SLEDAI-2K可能有助于预防停用后复发;减量期间复发者长期不良结局风险较高。
- 膜性狼疮肾炎患者较早停用免疫抑制剂是可行的;具体临床决策需结合原文结论及患者具体情况。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The optimal duration of immunosuppressive (IS) treatment for lupus nephritis (LN) remains uncertain. We assessed the prevalence and predictors of IS tapering and discontinuation (D/C) in LN patients. METHODS: Data from 137 inception cohort LN patients were analysed. We examined determinants of flares during tapering and after IS D/C, D/C achievement and time to D/C, and adverse long-term outcomes applying logistic and linear regression models. RESULTS: IS tapering was attempted in 111 (81%) patients, and D/C was achieved in 67.5%. Longer time to achieve complete renal response (CR) [odds ratio (OR): 1.07, P = 0.046] and higher SLEDAI-2K at tapering initiation (OR: 2.57, P = 0.008) were correlated with higher risk of renal flares during tapering. Persistent hydroxychloroquine use (≥2/3 of follow-up) (OR: 0.28, P = 0.08) and lower SLEDAI-2K 12 months before IS D/C (OR: 1.70, P = 0.013) decreased the risk of post-D/C flares. Adverse outcomes (>30% estimated glomerular filtration rate decline, chronic kidney disease, end-stage renal disease, death) at the end of follow-up (median 124 months) were more frequent in patients with flares during IS tapering (53% vs 16%, P < 0.0038) but did not differ between IS D/C achievers and non-achievers. In proliferative LN, differences mirrored those in the entire cohort, except for time to D/C, which occurred 20 months earlier in membranous vs proliferative LN (β = -19.8, P = 0.014). CONCLUSION: Earlier CR achievement and lower SLEDAI-2K at tapering initiation prevent flares during IS tapering, while persistent hydroxychloroquine use and lower SLEDAI-2K 12 months before IS D/C prevent post-D/C flares. Flares during tapering increase the risk of unfavourable long-term outcomes. Earlier IS D/C is feasible in membranous LN.
引用
- Panagiotopoulos A, Kapsia E, El Michelakis I, et al. Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes. Rheumatology (Oxford). 2025. PMID: 39037915. doi:10.1093/rheumatology/keae381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。